Panagiota Kravvariti

Ms. Panagiota Kravvariti


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Grigorios TsigkasGrigorios Tsigkas
Grigorios Tsigkas
Antonios Rigas PapapanagiotouAntonios Rigas Papapanagiotou
Antonios Rigas Papapanagiotou
APAggelos Papanikolaou
Aggelos Papanikolaou
APAthanasios Papageorgiou
Athanasios Papageorgiou
SGSpyridon Graidis
Spyridon Graidis
PDPeriklis Davlouros
Periklis Davlouros
Background and Objectives: Drug-coated balloon (DCB) angioplasty is a brief-contact endovascular drug-delivery technology in which efficacy must be generated during a single balloon inflation. Unlike drug-eluting stents (DES), DCBs have no permanent scaffold or polymer reservoir; they must preserve coating integrity during delivery, release drug at balloon-vessel contact, transfer drug into the arterial wall, and sustain biologically meaningful mural exposure after device removal. This review examines coronary DCBs as engineered platforms in which drug physicochemistry, excipient function, coating morphology, mechanical stability, balloon-vessel contact, tissue pharmacokinetics, and lesion substrate jointly shape angiographic and imaging response. Materials and Methods: By integrating bench coating-stability studies, computational delivery models, porcine pharmacokinetic and downstream-response studies, intravascular imaging, randomized clinical trials, and meta-analyses, this review proposes a platform-focused mechanistic framework. Results: DCB performance should not be interpreted as a simple drug-class effect. Devices carrying the same antiproliferative agent may differ because of coating cohesion, particle loss, excipient chemistry, adhesion switching, carrier design, dose density, release trigger, and temporary tissue-reservoir formation. Paclitaxel has physicochemical features favorable for brief-contact delivery, whereas limus-based balloons generally require more explicit delivery engineering through crystalline, nanoparticle, phospholipid, porous-infusion, or micro-reservoir architectures. Coating survival during tracking, triggered release, wall apposition, tissue deposition, intramural distribution, retention kinetics, and lesion preparation are treated as upstream determinants of late lumen loss, binary restenosis, late lumen enlargement, remodeling, and repeat revascularization. Conclusions: However, performance remains platform-specific rather than drug-class determined. The aim is not to provide a clinical algorithm, but to clarify how device engineering and lesion context shape the angiographic and imaging phenotype of contemporary coronary DCB therapy.

7 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Grigorios TsigkasGrigorios Tsigkas
Grigorios Tsigkas
Antonios Rigas PapapanagiotouAntonios Rigas Papapanagiotou
Antonios Rigas Papapanagiotou
APAggelos Papanikolaou
Aggelos Papanikolaou
APAthanasios Papageorgiou
Athanasios Papageorgiou
SGSpyridon Graidis
Spyridon Graidis
PDPeriklis Davlouros
Periklis Davlouros
Background and Objectives: Coronary drug-coated balloons (DCBs) deliver antiproliferative therapy during a single inflation without leaving a permanent scaffold or implanted drug reservoir. Their performance therefore depends on preservation of the coating during delivery, efficient vessel-wall transfer, and sufficient tissue exposure after balloon removal. This review critically examines the evidence for platform engineering, tissue exposure, and angiographic or intravascular imaging response. Materials and Methods: This narrative review synthesized English-language experimental, pharmacokinetic, imaging, and clinical evidence identified through the original PubMed, Scopus and Google Scholar searches and a documented PubMed search during revision on 9 September 2026. Exact queries, record dispositions and descriptive study appraisals are supplied; conference abstracts, preprints and unpublished data were excluded. Results: DCB performance is platform-specific rather than determined by drug class alone. Within both paclitaxel- and limus-based devices, excipient chemistry, coating or carrier architecture, release behavior, and retention strategy may influence drug delivery. Bench and computational studies identify potential transfer and drug-loss pathways, pharmacokinetic studies measure tissue exposure, and imaging and clinical studies assess morphology and outcomes separately. The cited human studies do not quantify coronary tissue drug exposure. Findings from unrelated platforms and models cannot establish a causal delivery-to-outcome pathway. Conclusions: Coronary DCBs should be evaluated as integrated, device-specific drug-delivery platforms. Standardized studies linking engineering performance and tissue exposure with imaging and clinical outcomes are needed.

Verified
Journal Article
Open access
PDF file
Grigorios TsigkasGrigorios Tsigkas
Grigorios Tsigkas
Antonios Rigas PapapanagiotouAntonios Rigas Papapanagiotou
Antonios Rigas Papapanagiotou
PKPanagiota Kravvariti
Panagiota Kravvariti
AKAsimenia Katsea
Asimenia Katsea
GVGeorgios Vasilagkos
Georgios Vasilagkos
PDPeriklis Davlouros
Periklis Davlouros
Transcatheter aortic valve implantation (TAVI) relieves valvular obstruction, but recovery of mobility, independence, exercise capacity, and health-related quality of life remains incomplete in many patients. This narrative review critically appraises cardiac rehabilitation (CR) after TAVI and proposes a needs-guided recovery framework. A search of MEDLINE, trial registries, guidelines, and citation networks through 4 September 2026 identified small, heterogeneous randomised trials and observational and implementation studies. Exercise-based interventions provide the most consistent, although imprecise, signal for increased peak oxygen uptake; effects on walking capacity, lower-extremity performance, disability, and quality of life are variable. No randomised trial has demonstrated reduced rehospitalisation or mortality, and favourable cohort associations remain susceptible to referral, survival, and healthy-participant bias. Contemporary guidelines support comprehensive CR but do not define a universal initiation time, exercise dose, or TAVI-specific safety thresholds. We propose proactive referral, confirmation of medical readiness, and assessment of cardiovascular stability, physical performance, frailty, nutrition, cognition, mood, falls risk, and contextual barriers to guide individualised exercise, nutritional, behavioural, and self-management interventions. Delivery, supervision, progression, and maintenance should match risk and access. Pragmatic trials should establish durability, safety, disability-free survival, healthcare utilisation, equity, and cost-effectiveness.